explore -WSS

explore

author：entertainment 2025-10-02 22:15:45 - browse：61

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Patients' immediate access to test results puts radiologists in a bind

WSS

AI models in health care face new federal disclosure requirements

Chemotherapy drug shortage eases slightly but still widespread

A virus, fished out of a lake, may have saved a man’s life

Stroke deaths set to near 10 million globally by 2050

Americans' trust in science, scientist continues decline: Report

Americans' trust in science, scientist continues decline: Report

explore

explore

knowledge

Medical records are filled with copy

Bristol 'take

Novavax promises a turnaround & Lilly roils the obesity market

FDA panel signals lack of confidence in Amgen cancer drug data

Activists slam private health insurers over coverage restrictions

A Q&A with the global head of Boehringer Ingelheim's innovation unit

In age of alternative facts, a scholarly course on calling out crap

Pharma patents targeted by Biden in move to slash drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Bristol 'take

explore

SCOTUS to consider access to abortion pill mifepristone

Bill would stop addiction treatment from triggering child abuse inquiry

Teach medical students about patients with intellectual disabilities

Why age limits for politicians are a terrible idea

CMS should re

FDA panel signals lack of confidence in Amgen cancer drug data

hotspot

knowledge

hotspot

focus